Peptides FDA Update: HHS Lets Pharmacies Compound 6 Peptides

What is the big peptides FDA update everyone is talking about? On October 28, 2026, the US Department of Health and Human Services (HHS) said it will not take enforcement action against state-licensed pharmacies and doctors who compound six unapproved peptides. The six are BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. This is not an FDA approval. It is a temporary pause on enforcement while the FDA decides, through formal rules, whether pharmacies can use these ingredients for good.

If you take a GLP-1 like Ozempic, Wegovy or Zepbound, nothing about your medicine changes. Here is what the policy says, what it does not say, and why it matters if you have seen these peptides pushed online.

Peptides FDA update: what HHS announced

The notice was signed by Health Secretary Robert F. Kennedy Jr. Its official title is "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances."

The notice also says plainly that compounded drugs "are not FDA-approved," and that the FDA does not review their safety, effectiveness or quality before they are sold. HHS says it made the move "to expand and improve patient access," pointing to strong interest in these peptides and the lack of approved versions.

Which 6 peptides are covered, and what does the FDA know about them?

Reuters reported the uses each peptide is promoted for. The FDA's notes come from its own page on bulk drug substances that may raise safety risks.

BPC-157 and TB-500 are often sold together as the "Wolverine stack." Notice the pattern in the last column. For most of these peptides, the FDA says it has found little or no data from people at all.

Are peptides FDA approved now?

No, and this is the part most headlines blur. The policy changes what the FDA will enforce, not what the FDA has approved.

• Not an approval. The six peptides are still unapproved drugs. No company has proven to the FDA that they are safe or that they work.
• Not a permanent rule. HHS calls it interim. The notice says it "is not binding on HHS or the public."
• Not a free-for-all. Reuters reported that compounders must meet conditions on ingredient quality, manufacturing standards, labeling, safety reporting and patient-specific prescriptions. NBC News reported that pharmacies must certify the identity and purity of the peptides and report side effects.
• States still decide. State pharmacy boards set many compounding rules. Industry groups told Reuters that some states may not follow the federal move.

Some peptides are FDA-approved, of course. Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and liraglutide (Saxenda) are all peptide drugs that went through full trials. Our GLP-1 vs peptides guide maps out which is which.

How did we get here?

The policy is the latest step in a fast-moving year for peptides:

• September 2023: The FDA put BPC-157 and other peptides in "Category 2," its list of bulk substances that may raise significant safety risks. That stopped most pharmacies from compounding them.
• April 2026: The FDA said it would take 12 peptides off Category 2 after their nominations were withdrawn. That did not make them legal to compound.
• June 29, 2026: FDA staff recommended against adding seven peptides to the list pharmacies can use.
• July 23 to 24, 2026: The FDA's Pharmacy Compounding Advisory Committee voted to recommend adding the six. BPC-157, KPV and TB-500 each passed 8 to 6, with one abstention. NBC News reported that several new panel members had ties to the peptide industry. HHS said all members cleared standard ethics checks.
• October 28, 2026: HHS filed the enforcement policy.

Supporters, like the American Academy of Peptide Medicine, called it a milestone. Critics, including former FDA official Dr. Peter Lurie, said the agency was "turning a blind eye" to unproven drugs.

Does this cover retatrutide or "research use only" vials?

No on both counts.

• Retatrutide is not on the list. It is an experimental Eli Lilly GLP-1, GIP and glucagon drug still in phase 3. Selling it is still illegal. Our guide on whether retatrutide is legal explains why.
• Research-use-only vials are not compounding. The policy covers licensed 503A pharmacies and doctors making a drug for a named patient. Websites selling vials "not for human use" are outside it. HHS says one goal is to move people away from those sellers.
• Compounded semaglutide and tirzepatide are a separate issue. The notice does not mention them. Our compounded GLP-1 guide covers those rules.

What this means if you are on a GLP-1

Expect to see more ads. Reuters reported that telehealth companies such as Hims & Hers have been preparing to offer peptides, and analysts estimate the market could reach $2 billion to $3 billion. You may see MOTS-c sold as a fat-loss or "muscle-sparing" add-on to your GLP-1.

Before you add anything, ask your prescriber these questions:

1. Is there any human trial showing this peptide works for my goal?
2. Could it interact with my GLP-1 or my other medicines?
3. Is the pharmacy state-licensed, and will my doctor write a patient-specific prescription?
4. Who do I call, and what gets reported, if I have a side effect?

The muscle-loss worry is real, but the fixes with the strongest evidence are not new peptides. They are enough protein and regular strength training. Sharpy turns that into one daily protein target and one 20-minute workout, so you protect muscle with habits that have been studied in people. Start with our protein target guide and resistance training guide.

If you are pregnant, under 18, have a history of an eating disorder or have a serious health condition, talk to your doctor before trying any peptide.

When will peptides be FDA approved?

There is no date. For a peptide to be approved as a drug, a company has to run trials and file an application with the FDA, and none of the six has done that. Separately, the FDA may propose adding some or all of them to the 503A bulks list. That needs a proposed rule, a comment period and a final rule, which NBC News noted can take several months. Another advisory meeting on five more peptides, including GHK-Cu, is expected before the end of February 2027.

The bottom line

The October 2026 peptides FDA update makes six peptides easier to get from licensed compounders. It does not make them approved, proven or risk-free, and it does not touch your GLP-1 prescription. Treat any peptide add-on as a question for your prescriber, not a shortcut. For the part of weight loss you control every day, Sharpy keeps your protein, workouts and Shape Score in one place.

Sources

• HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Federal Register document 2026-22192
• Reuters via GV Wire: US health department to allow temporary sale of some unapproved peptides (Oct 28, 2026)
• NBC News: RFK Jr. takes shortcut to make some unapproved peptides available for use (Oct 28, 2026)
• FDA: Certain bulk drug substances for use in compounding that may present significant safety risks
• Holland & Knight: Peptides at a Crossroads (Oct 2026)